A molecular classification predicts the prognosis and the benefit of a cell cycle inhibitor in metastatic breast cancer

In a study published in the Journal of Clinical Oncology, researchers from the Hospital Clínic-IDIBAPS-UB and SOLTI showed the predictive capacity of the 4 molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched and Basal-like).

From left to right, Nuria Chic, Laia Paré, Olga Martínez-Sáez, Fara Brasó and Aleix Prat (Photo: Francisco Avia – Hospital Clínic).